Anticancer research · 2003
Reduction of p53 dosage renders mice hypersensitive to 7, 12-dimethylbenz(alpha) anthracene-induced salivary gland tumorigenesis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ide Fumio, Kitada Munenori, Sakashita Hideaki, Kusama Kaoru
Аннотация
BACKGROUND: The role of p53 during the evolutionary steps of experimental salivary gland tumorigenesis has not been fully elucidated.
MATERIALS AND METHODS: Each genotype group of p53-deficient mice received a single intrasubmandibular gland injection of 1 mg of 7, 12-dimethylbenz(a)anthracene. In addition to the routine histopathological examination, immunohistochemical detection of p53 protein and molecular biological analysis of wild-type p53 allele status in the p53+/- tumors developed were performed.
RESULTS: Fourteen weeks following injection, submandibular gland tumors developed in 100% of p53-/- and 70% of p53+/- mice, whereas only 10% of p53+/+ mice yielded tumors. Salivary gland tumors in p53-deficient mice were predominantly sarcomas (70%). In 64% of p53+/- tumors, overexpression of a mutant version of p53 protein was evident. Loss of the wild-type allele of p53 could not be detected in all p53+/- tumors.
CONCLUSION: The earlier tumor development in p53-deficient mice provides the in vivo evidence that reduction of p53 dosage or possibly p53 haploinsufficiency might be sufficient to promote salivary gland tumorigenesis.
MATERIALS AND METHODS: Each genotype group of p53-deficient mice received a single intrasubmandibular gland injection of 1 mg of 7, 12-dimethylbenz(a)anthracene. In addition to the routine histopathological examination, immunohistochemical detection of p53 protein and molecular biological analysis of wild-type p53 allele status in the p53+/- tumors developed were performed.
RESULTS: Fourteen weeks following injection, submandibular gland tumors developed in 100% of p53-/- and 70% of p53+/- mice, whereas only 10% of p53+/+ mice yielded tumors. Salivary gland tumors in p53-deficient mice were predominantly sarcomas (70%). In 64% of p53+/- tumors, overexpression of a mutant version of p53 protein was evident. Loss of the wild-type allele of p53 could not be detected in all p53+/- tumors.
CONCLUSION: The earlier tumor development in p53-deficient mice provides the in vivo evidence that reduction of p53 dosage or possibly p53 haploinsufficiency might be sufficient to promote salivary gland tumorigenesis.